Sharps Technology

Sharps Technology Retained Earnings

The Retained Earnings of Sharps Technology (STSS) as of Nov 4, 2026 is -316.95 M USD. In the previous year, Retained Earnings was -34.45 M USD — a change of 820.15% (lower).

Retained Earnings

-316.95 MUSD

YoY

820.15%

Last updated:

Retained Earnings of Sharps Technology is 2025 -316.95 M USD. Retained Earnings of Sharps Technology was 2024 -34.45 M USD. It decreases by 820.15% lower compared to the previous year.

The Sharps Technology Retained Earnings history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Retained Earnings
Date
Retained Earnings
Jan 1, 2019
-3.66 M USD
Jan 1, 2020
-6.00 M USD
Jan 1, 2021
-10.67 M USD
Jan 1, 2022
-15.31 M USD
Jan 1, 2023
-25.15 M USD
Jan 1, 2024
-34.45 M USD
Jan 1, 2025
-316.95 M USD
The Sharps Technology Retained Earnings history
YEARRetained EarningsYoY
-316.95 MUSD+820.15%
-34.45 MUSD+36.96%
-25.15 MUSD+64.29%
-15.31 MUSD+43.49%
-10.67 MUSD+77.70%
-6.00 MUSD+63.89%
-3.66 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sharps Technology Stock analysis

What does Sharps Technology do? Sharps Technology Inc. generates revenue through the development and manufacturing of innovative drug delivery systems, particularly its Sharps Provensa line of smart safety syringes. The company offers products like Sharps Provensa PS-3ML, Sharps Provensa RS-1ML, and Sharps Provensa PSU-0.3 ML, designed to address global healthcare challenges such as minimizing vaccine waste and providing needlestick protection. Its Ultra-Low Waste syringes are specifically marketed to healthcare providers and institutions seeking efficient solutions for vaccine administration. The firm also distributes Sharps Provensa RTF PS Glass Prefillable Syringes, targeting hospitals and clinics that require reliable, pre-filled syringe systems. The company's revenue streams are driven by the commercialization of its patented safety syringe technology, with a focus on healthcare facilities and organizations involved in vaccine distribution. Sharps Provensa PS-1ML and other models are positioned for use in clinical settings where safety and waste reduction are critical. The manufacturing facility, located over 160 kilometers from Budapest Airport, supports production for global distribution, though the business description does not specify exact buyer segments beyond healthcare providers. Safegard Medical, Inc., the wholly owned subsidiary, likely contributes to the company's product portfolio and manufacturing capabilities, though the business description does not detail its specific role in revenue generation. The firm's products are designed to meet the needs of healthcare systems aiming to reduce waste and improve safety, with no mention of additional revenue sources or partnerships beyond its core product lines. Sharps Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sharps Technology stock

Retained Earnings of Sharps Technology is -316.95 M USD in 2025.

Retained Earnings of Sharps Technology changed from -34.45 M USD to -316.95 M USD, representing a 820.15% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Retained Earnings Sharps Technology since 2006 – with annual values, charts, and detailed analysis.

Retained earnings are the cumulative net income kept in the business rather than paid out as dividends. They fund future growth and operations.

Retained Earnings's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Retained Earnings's Sharps Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Sharps Technology

All Key Metrics — Sharps Technology